- Aprile 2020
- COVID-19 emergency: clinical trials and early access to drugs
- The Regulation (EU) 2020/354 revises and updates the list of intended uses of feed intended for particular nutritional purposes
- Marzo 2020
- COVID-19 and consumer protection: the impact on selling and advertising practices and early reactions from relevant Italian bodies
- CJEU Advocate General says that samples of pharmaceutical products cannot be provided to pharmacists
- Cura Italia Decree and Ordinance 630/2020: new rules for public contracts
- COVID-19 and IP rights: production of life-saving respiratory valves using 3D printers
- Febbraio 2020
- Medicine and medical device e-commerce: regulatory restrictions and opportunities
- EDPS: clarification on data protection and scientific research
- Early lessons from the ECJ on access to documents included in a marketing authorization dossier
- Venture capital watch: an overview of 2019 investments
- Traditional herbal medicinal products and nutritional supplements: criteria of distinction
- Important news regarding non-therapeutic use of cannabis: the Italian Ministry of Health finally sets limits for THC in hemp food products
- Stability Law 2020: news about homeopathic medicines
- Tender for the supply of medicine based on a patented active ingredient: a legal profile
- Who can request authorization to advertise medicines? Answers from the AGCM
- Class I medical device manufacturers may benefit from the transitional period under the MDR
- Dicembre 2019
- EU commission publishes a new version of the draft Q&A on the application of the clinical trials regulation
- Regional Administrative Court of Tuscany: recent judgment on biosimilars
- News about advertising medical devices on Facebook: updates from the Ministry of Health
- Italian Medicines Agency: publication of the final version of the agreement on conducting clinical trials on medicines